Telix Pharmaceuticals Limited
TLX
$9.36
-$0.07-0.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 42.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 42.89% | |||
| Cost of Revenue | 0.00% | 91.20% | |||
| Gross Profit | 0.00% | 12.77% | |||
| SG&A Expenses | 0.00% | 32.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.00% | 3,536.49% | |||
| Total Operating Expenses | 0.00% | 56.55% | |||
| Operating Income | 0.00% | -105.02% | |||
| Income Before Tax | 0.00% | -134.72% | |||
| Income Tax Expenses | 0.00% | -452.06% | |||
| Earnings from Continuing Operations | 0.00% | -117.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | -117.36% | |||
| EBIT | 0.00% | -105.02% | |||
| EBITDA | 0.00% | -75.97% | |||
| EPS Basic | 0.00% | -117.26% | |||
| Normalized Basic EPS | 0.00% | -112.04% | |||
| EPS Diluted | 0.00% | -118.09% | |||
| Normalized Diluted EPS | 0.00% | -112.68% | |||
| Average Basic Shares Outstanding | 0.00% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.00% | -4.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||